Literature DB >> 3358909

Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.

J A Goldberg1, D J Kerr, N Willmott, J H McKillop, C S McArdle.   

Abstract

By measuring peripheral drug levels in plasma, the effect of combining albumin microspheres with angiotensin II on systemic exposure to 5FU when administered by bolus injection into the hepatic artery in patients with advanced colorectal liver metastases has been assessed. The results suggest that despite hepatic arterial administration of 5FU, there was no reduction in systemic exposure when compared with that associated with intravenous injection of the same dose. Neither albumin microspheres nor angiotensin II appeared to improve the regional advantage. There have been a number of reports relating the plasma levels of cytotoxic agents with pharmacodynamic parameters. We have shown significant direct correlations between 5FU clearance and 1 week post treatment platelet and white cell counts, and an inverse relationship between the area under the 5FU plasma concentration-time curve (AUC) and 1 week post treatment platelet count and white cell count respectively.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358909      PMCID: PMC2246442          DOI: 10.1038/bjc.1988.39

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

Authors:  W D Ensminger; A Rosowsky; V Raso; D C Levin; M Glode; S Come; G Steele; E Frei
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

2.  Control of gene expression in carbohydrate, pyrimidine and DNA metabolism.

Authors:  G Weber; S F Queener; J A Ferdinandus
Journal:  Adv Enzyme Regul       Date:  1970

Review 3.  Colorectal liver metastases--to treat or not to treat?

Authors:  I Taylor
Journal:  Br J Surg       Date:  1985-07       Impact factor: 6.939

Review 4.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Serum albumin beads: an injectable, biodegradable system for the sustained release of drugs.

Authors:  T K Lee; T D Sokoloski; G P Royer
Journal:  Science       Date:  1981-07-10       Impact factor: 47.728

6.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

7.  Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer.

Authors:  Y Sasaki; S Imaoka; Y Hasegawa; S Nakano; O Ishikawa; H Ohigashi; K Taniguchi; H Koyama; T Iwanaga; T Terasawa
Journal:  Cancer       Date:  1985-01-15       Impact factor: 6.860

8.  Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.

Authors:  J G Wagner; J W Gyves; P L Stetson; S C Walker-Andrews; I S Wollner; M K Cochran; W D Ensminger
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

9.  Adriamycin-loaded albumin microspheres: preparation, in vivo distribution and release in the rat.

Authors:  N Willmott; J Cummings; J F Stuart; A T Florence
Journal:  Biopharm Drug Dispos       Date:  1985 Jan-Mar       Impact factor: 1.627

10.  Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes.

Authors:  J M Collins; R L Dedrick; F G King; J L Speyer; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

View more
  19 in total

Review 1.  Pharmacokinetically guided administration of chemotherapeutic agents.

Authors:  H J van den Bongard; R A Mathôt; J H Beijnen; J H Schellens
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

2.  Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.

Authors:  Ronald Gieschke; Hans-Ulrich Burger; Bruno Reigner; Karen S Blesch; Jean-Louis Steimer
Journal:  Br J Clin Pharmacol       Date:  2003-03       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

4.  Relationship between the pharmacokinetics and toxicity of mitozolomide.

Authors:  D J Kerr; J A Slack; P Secrett; M F Stevens; G R Blackledge; C Bradley; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Limited-sampling models for anticancer agents.

Authors:  L J van Warmerdam; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 6.  Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer.

Authors:  F G Jansman; D T Sleijfer; J L Coenen; J C De Graaf; J R Brouwers
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 7.  Can pharmacokinetic monitoring improve clinical use of fluorouracil?

Authors:  A M Young; S Daryanani; D J Kerr
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

8.  Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.

Authors:  Ali I Shamseddine; Mohammad J Khalifeh; Fadi H Mourad; Aref A Chehal; Aghiad Al-Kutoubi; Jaber Abbas; Mohammad Z Habbal; Lida A Malaeb; Anwar B Bikhazi
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

9.  Combined haemoperfusion, haemofiltration and haemodialysis for systemic detoxification in locoregional 5-fluorouracil therapy.

Authors:  F Keller; U Gallkowski; W Roth; J Boese-Landgraf
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 10.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.